June 27, 2025
Dr Prasad Devarajan is a pediatric nephrologist at the Cincinnati Children’s
Hospital Medical Center. He specializes in pediatric acute kidney injury
and kidney stone disease. He has authored more than 350 peer-reviewed
publications, 100 book chapters, and delivered more than 250 invited
lectures nationally and internationally. Dr Devarajan has been listed in
Thomson Reuters “World’s Most Influential Scientific Minds” in recognition
of ranking among the top 1% of researchers for most cited publications in
the entire field of medicine.
Dr Devarajan will introduce an FDA-approved therapy for patients with
Primary Hyperoxaluria Type 1 (PH1) that can help address the underlying
cause of the disease. PH1 is a rare, autosomal recessive genetic disorder
that leads to kidney stones and progressive kidney damage. It is caused by
a genetic mutation that results in the excessive production of oxalate by the
liver. Attend this session to learn more about PH1 and a treatment option
that can help address the overproduction of oxalate.
Click to register. Registration is required to receive link for program. This
is a promotional education presentation sponsored by Novo Nordisk; it
will not be certified for continuing medical education credit. The faculty will
be compensated for their participation in this program. Program contains
product-related information.
